An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma
…, N Bremond, MC Rouchon, F Hurbin… - Thrombosis and …, 2011 - thieme-connect.com
Pharmacokinetic analyses of clopidogrel are hampered by the existence of multiple active
metabolite isomers (H1 to H4) and their instability in blood. We sought to retest the …
metabolite isomers (H1 to H4) and their instability in blood. We sought to retest the …
Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active …
…, D Fabre, X Boulenc, G Fabre, E Sultan, F Hurbin - Drug Metabolism and …, 2015 - ASPET
Clopidogrel is a prodrug that needs to be converted to its active metabolite (clopi-H4) in two
sequential cytochrome P450 (P450)-dependent steps. In the present study, a dynamic …
sequential cytochrome P450 (P450)-dependent steps. In the present study, a dynamic …
[HTML][HTML] Population pharmacokinetic analysis of alirocumab in healthy volunteers or hypercholesterolemic subjects using a Michaelis–Menten approximation of a …
JM Martinez, A Brunet, F Hurbin, AT DiCioccio… - Clinical …, 2019 - Springer
Background Alirocumab, a human monoclonal antibody, inhibits proprotein convertase
subtilisin/kexin type 9 (PCSK9) to significantly reduce low-density lipoprotein cholesterol levels; …
subtilisin/kexin type 9 (PCSK9) to significantly reduce low-density lipoprotein cholesterol levels; …
Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite
…, J Shi, L Perrin, W Brian, R Van Horn, F Hurbin - Drug Metabolism and …, 2012 - ASPET
Clopidogrel is an antiplatelet agent widely used in cardiovascular diseases and an inactive
prodrug that needs to be converted to an active metabolite in two sequential metabolic steps. …
prodrug that needs to be converted to an active metabolite in two sequential metabolic steps. …
[HTML][HTML] Target-mediated drug disposition population pharmacokinetics model of alirocumab in healthy volunteers and patients: pooled analysis of randomized phase …
…, L Lohan, S Khier, A Brunet, F Hurbin… - Clinical …, 2017 - Springer
Background and Objective Proprotein convertase subtilisin/kexin type 9 inhibition with
monoclonal antibodies such as alirocumab significantly reduces low-density lipoprotein-…
monoclonal antibodies such as alirocumab significantly reduces low-density lipoprotein-…
Endothelial‐protective effects of a G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist, SAR247799, in type‐2 diabetes rats and a randomized placebo …
…, R Sansone, C Heiss, O Vitse, F Hurbin… - British journal of …, 2021 - Wiley Online Library
Aims SAR247799 is a G‐protein‐biased sphingosine‐1 phosphate receptor‐1 (S1P 1 )
agonist designed to activate endothelial S1P 1 and provide endothelial‐protective properties, …
agonist designed to activate endothelial S1P 1 and provide endothelial‐protective properties, …
Estimation of flavin-containing monooxygenase activity in intact hepatocyte monolayers of rat, hamster, rabbit, dog and human by using N-oxidation of benzydamine
G Ubeaud, CD Schiller, F Hurbin, D Jaeck… - European journal of …, 1999 - Elsevier
The flavin-containing monooxygenase (FMO)-dependent N-oxidation of benzydamine has
been assessed as a method for monitoring the activity of FMOs in monolayer cultures of …
been assessed as a method for monitoring the activity of FMOs in monolayer cultures of …
First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G‐protein …
…, G Golor, A Tardat, O Vitse, F Hurbin… - British Journal of …, 2021 - Wiley Online Library
Aims SAR247799 is a selective G‐protein‐biased sphingosine‐1 phosphate receptor‐1 (S1P
1 ) agonist with potential to restore endothelial function in vascular pathologies. …
1 ) agonist with potential to restore endothelial function in vascular pathologies. …
Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men
F Hurbin, X Boulenc, N Daskalakis… - The Journal of …, 2012 - Wiley Online Library
Clopidogrel requires CYP450‐mediated hepatic metabolism to form its active metabolite (clopi‐H4).
This randomized, placebo‐controlled, crossover study was designed to characterize …
This randomized, placebo‐controlled, crossover study was designed to characterize …
[HTML][HTML] Population pharmacokinetic/pharmacodynamic analysis of alirocumab in healthy volunteers or hypercholesterolemic subjects using an indirect response …
X Nicolas, N Djebli, C Rauch, A Brunet, F Hurbin… - Clinical …, 2019 - Springer
Background Alirocumab, a human monoclonal antibody against proprotein convertase
subtilisin/kexin type 9 (PCSK9), significantly lowers low-density lipoprotein cholesterol levels. …
subtilisin/kexin type 9 (PCSK9), significantly lowers low-density lipoprotein cholesterol levels. …